Open Access

Identification of CSF biomarkers by proteomicsin Guillain‑Barré syndrome

  • Authors:
    • Pei Li
    • Sujie Wang
    • Ruili Zhang
    • Jian Pei
    • Lili Chen
    • Yibin Cao
    • Haoliang Zhang
    • Guofeng Yang
  • View Affiliations

  • Published online on: May 2, 2018     https://doi.org/10.3892/etm.2018.6117
  • Pages:5177-5182
  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

The purpose of the present study was to screen for differentially expressed proteins in the cerebrospinal fluid (CSF) of patients with Guillain‑Barré syndrome (GBS). The identification of differentially expressed protein can provide new targets for understanding the pathogenic mechanism, early clinical diagnosis, prognosis and for measuring the effectiveness of interventions. We enrolled 50 GBS patients and 50 meningitis patients (control group) to compare protein expression in CSF. The GBS cases included 28 cases of acute inflammatory demyelinating polyneuropathy (AIDP) and 22 cases of acute motor axonal neuropathy (AMAN). We then performed two‑dimensional differential in‑gel electrophoresis combined with matrix‑assisted laser desorption/ionization time‑of‑flight mass spectrometry to identify the differentially expressed proteins. The expression levels were validated by ELISA, and their accuracy, sensitivity, and specificity in GBS diagnosis were analyzed by the receiver operating characteristic curve. Three differentially expressed proteins were identified, including the upregulated haptoglobin (Hp) and heat shock protein 70 (Hsp70), and downregulated cystatin C. There were no significant differences between the AIDP and AMAN patients in the positive rates and quantitative expression levels of the three differentially expressed proteins. The accuracy of Hp in the diagnosis of GBS was 0.835, sensitivity was 86.7%, and specificity was 88.2%. The accuracy of cystatin C in the diagnosis of GBS was 0.827, sensitivity was 85.5%, and specificity was 89.7%. The accuracy of Hsp70 in the diagnosis of GBS was 0.841, its sensitivity was 87.8%, and its specificity was 92.3%. Hp and Hsp70 are significantly increased, and cystatin C is downregulated in CSF of GBS patients, which provides important biomarkers for early GBS diagnosis, although these proteins cannot distinguish AIDP and AMAN.

Related Articles

Journal Cover

June 2018
Volume 15 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

2016 Impact Factor: 1.261
Ranked #50/128 Medicine Research and Experimental
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Li, P., Wang, S., Zhang, R., Pei, J., Chen, L., Cao, Y. ... Yang, G. (2018). Identification of CSF biomarkers by proteomicsin Guillain‑Barré syndrome. Experimental and Therapeutic Medicine, 15, 5177-5182. https://doi.org/10.3892/etm.2018.6117
MLA
Li, P., Wang, S., Zhang, R., Pei, J., Chen, L., Cao, Y., Zhang, H., Yang, G."Identification of CSF biomarkers by proteomicsin Guillain‑Barré syndrome". Experimental and Therapeutic Medicine 15.6 (2018): 5177-5182.
Chicago
Li, P., Wang, S., Zhang, R., Pei, J., Chen, L., Cao, Y., Zhang, H., Yang, G."Identification of CSF biomarkers by proteomicsin Guillain‑Barré syndrome". Experimental and Therapeutic Medicine 15, no. 6 (2018): 5177-5182. https://doi.org/10.3892/etm.2018.6117